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Abstract: This article reflects upon the introduction of nonmedical prescribing in the United
Kingdom and describes the historical developments within the National Health Service over the
last 2 decades, together with an assessment of the impact of this prescribing for various stakehold-
ers, drawing upon relevant research. We argue that a number of issues are associated with the intro-
duction and development of nonmedical prescribing, including benefits to patients, the promise
of increased autonomy for professions such as nursing and pharmacy, explicit and implicit gov-
ernment objectives, and threats to medical dominance and autonomy. Key words: Non-medical
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THIS ARTICLE reflects upon the introduc-tion of nonmedical prescribing (NMP)
in the United Kingdom and describes the
historical developments within the National
Health Service (NHS) over the last 2 decades,
together with an assessment of the impact
of this prescribing for various stakeholders,
drawing upon relevant research. We argue
that a number of issues are associated with
the introduction and development of NMP, in-
cluding benefits to patients, the promise of
increased autonomy for professions such as
nursing and pharmacy, explicit and implicit
government objectives, and threats to med-
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ical dominance and autonomy. From these
various and potentially conflicting interests—
from something “as simple as giving prescrib-
ing rights” (Jones, 1999, p. 5) to a “danger-
ous, uncontrolled experiment”(Horton, 2003,
p. 1876)—an attempt is made to consider
how successful NMP in the United Kingdom
has been and how it may evolve in the coming
years.
THE HISTORY OF NMP IN THE
UNITED KINGDOM
To understand the significance of NMP, a
relevant starting point is the statutory control
of medicines in the United Kingdom, which
has undergone a number of changes in recent
years. Medicines in the United Kingdom have
been increasingly regulated since the end
of the 1800s, culminating in the Medicines
Act (1968), which consolidated much pre-
vious legislation and defined medicines in
terms of prescription-only medicines (POMs),
pharmacy-only (P) medicines, and general
sales-listed (GSL) medicines. POMs could be
prescribed only by authorized practitioners—
qualified doctors and dentists—using either
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private prescriptions or, more commonly
after 1948, NHS prescriptions. This situa-
tion effectively made the medical profession
gatekeepers for medicines, and this was cer-
tainly the case for those medicines considered
more likely to cause harm or abuse such as
controlled drugs such as morphine. Although
pharmacists retained a counter-prescribing
role selling P and GSL medicines, since the
1980s, there has been a trend toward in-
creasing deregulation of POMs (Blenkinsopp
& Bradley, 1996) to P or GSL status in phar-
macies and general retail outlets. These de-
velopments represented the first indication
that medical control of medicines might be
challenged (Britten, 2001) and were joined
by a potentially more far-reaching proposal
to extend prescribing rights to nonmedical
professionals.
This arose in the form of the Cumber-
lege report (Department of Health and So-
cial Security, 1986), which concluded that
district nurses and healthcare visitors in-
volved in neighborhood nursing should be al-
lowed limited prescribing rights. This led to
an advisory group being convened to con-
sider nurse prescribing, which concluded in
Table 1. Historical development of nonmedical prescribing in the United Kingdom
1992 Primary legislation for independent nurse prescribing enacted (Medicinal Products:
Prescription by Nurses etc Act 1992) for district nurses (DNs) and healthcare
visitors (HVs)
1994 First prescribing pilots by nurses and introduction of Nurse Prescribers’ Formulary
(NPF)
1998 National independent nurse prescribing possible for DNs and HVs (with V100
training) from revised NPF
2001 All nurses (with V100 qualification) able to prescribe from NPF
2002 Prescribing from Nurse Prescribers’ Extended Formulary possible for V200 trained
nurses, including more prescription-only medicines
April 2003 Legislation enabling suitably trained nurses and pharmacists to practice as
supplementary prescribers (Health and Social Care Act, 2001) introduced
April 2005 Regulatory changes allowed nurse and pharmacist supplementary prescribers to
prescribe all controlled drugs except Sch.1 (The Misuse of Drugs (Amendment)
(No. 2) Regulations 2005) and unlicensed medicines
May 2005 Suitably trained physiotherapists, chiropodists/podiatrists, radiographers, and
optometrists able to practice as supplementary prescribers
May 2006 Legislation enabling nurse independent prescribing (formerly extended formulary
nurse prescribing) and independent prescribing for pharmacists introduced
the Crown report (Department of Health
[DoH], 1989) that there were inefficient prac-
tices in primary care that nurse prescribing
could rectify. In particular, it was noted that:
“a doctor often rubber-stamps a prescribing
decision taken by a nurse [. . .] which is de-
meaning to both nurses and doctors [. . .and]
action is now needed to align prescribing
power with professional responsibility”(DoH,
1989, p. 12). By 1994, a national nurse pre-
scribers’ formulary for district nurses and
healthcare visitors had been established and
prescribing without a doctor was undertaken
in several pilot sites following legislation. Ap-
pliances such as dressings, catheters, stoma
products, and some medicines were included
in the formulary (Nurse Prescribers’ Formu-
lary [NPF], 1994) (Table 1), and from 1998, all
suitably trained district nurses and healthcare
visitors could prescribe from the NPF.
A second Crown report (DoH, 1999) set out
more far-reaching proposals for the prescrib-
ing and supply of medicines in the United
Kingdom, including not only nurses but also
pharmacists as potential prescribers, and pro-
posals included a dependent, supplementary
form of prescribing. This was introduced in
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2003 following legislation, allowing suitably
trained nurses and pharmacists to prescribe
all medicines except controlled and unli-
censed drugs in accordance with a clinical
management plan (CMP) produced after an
initial doctor’s diagnosis and with the agree-
ment of the doctor, the supplementary pre-
scriber, and the patient. Controlled drugs
were also prescribable by nurses and pharma-
cists using supplementary prescribing from
2005.
In 2005, allied healthcare professionals
such as physiotherapists, radiographers, po-
diatrists, and optometrists were also able
to become supplementary prescribers (DoH,
2005), reflecting the rapid development of
NMP in the United Kingdom, which could
be contrasted with the more gradual intro-
duction of prescribing rights in the United
States, for example, for nurses (Armstrong
et al., 1995) and pharmacists (Emmerton
et al., 2005). The most recent development
in NMP involved legislation permitting trained
nurses and pharmacists to independently pre-
scribe almost all medicines within their clin-
ical competence (DoH, 2006). This repre-
sented the first independent prescribing op-
portunity for pharmacists and consolidated
the position of nurse prescribers, who were
then able to access almost the full formu-
lary of medicines, as per doctors. Some con-
trolled drugs remain excluded from indepen-
dent NMP, although at the time of writing
(September 2007), this is currently under
review.
IN WHOSE INTERESTS? IMPLICATIONS
OF NMP FOR UK STAKEHOLDERS
This historical summary overlooks how key
stakeholders have both sought to influence
and also been influenced by such changes
to prescribing in the United Kingdom. These
stakeholder groups, including the nursing,
pharmacy, and medical professions and their
members, patients, and also the UK govern-
ment, are now considered and references
to research are also made, highlighting cur-
rent knowledge about NMP in the United
Kingdom.
The nursing profession
Nurses were the first nonmedical profes-
sionals to gain prescribing rights, and a num-
ber of reasons may be advanced as to why
this occurred. This description of the devel-
opment of NMP hinted at several reasons for
nurses acquiring prescribing privileges: first,
allowing nurses to prescribe addressed the
unsatisfactory and inefficient system whereby
nurses had to ask doctors to write prescrip-
tions for conditions that were already ef-
fectively under their management, such as
wound care and incontinence; second, NMP
offered a better deployment of the nurses’
skills and afforded them greater professional
autonomy, challenging their traditionally sub-
ordinate position within the division of la-
bor in healthcare (Turner, 1995). However,
at the same time, the nursing profession had
become an increasingly vocal (and indeed
powerful) profession and its effective politi-
cal lobbying may also have played a part in
nurses being afforded prescribing privileges
(Sims & Gardiner, 1999) before pharmacists.
That nurses became prescribers before phar-
macists may also be explained by the na-
ture of the respective professions and their
members as well—most nurses are NHS em-
ployed, whereas the majority of UK pharma-
cists still work in the community (or retail)
sector as pharmacy owners or increasingly
as locums or employees and have been per-
ceived to be commercially motivated “shop-
keepers” (Eaton & Webb, 1979; Hughes &
McCann, 2003). Perceptions of these motiva-
tions may not have been conducive to phar-
macists obtaining prescribing status. In addi-
tion, nurses have also enjoyed a much closer
proximity to patients (Malone, 2003) and doc-
tors than pharmacists, which also made pre-
scribing a more viable proposition in terms of
understanding the background and needs of
the patient and securing medical prescribers’
necessary trust and confidence in nurses’
abilities.
There are now almost 42,000 nurses with
a prescribing qualification in the United King-
dom (around 6% of all UK registered nurses),
of whom nearly 13,000 are able to prescribe
from the full formulary using independent
Nonmedical Prescribing in the United Kingdom 247
or supplementary prescribing (Nursing and
Midwifery Council, 2007). Furthermore, re-
search suggests that nurses appear to have
welcomed their prescribing roles (Luker et al.,
1997; Rodden 2001) and early frustrations
about prescribing from a limited formulary
were identified but allayed by the subsequent
legislative changes to full formulary prescrib-
ing. Despite the benefits of increased pro-
fessional autonomy, there is evidence, how-
ever, that nurses have been cautious in un-
dertaking prescribing and may even be reluc-
tant to do so once qualified (Bradley et al.,
2007; Hall et al., 2006). Linked to the ben-
efit of increased professional autonomy is
the prospect that NMP will enhance percep-
tions of nurses through gaining new skills
and knowledge. An opposing concern, how-
ever, is that NMP focuses upon nursing qua
medicine rather than nursing qua nursing
(Fawcett, 2007) with a resultant overempha-
sis upon a biomedical model of curing rather
than what has been described in the past
as the traditional value of holistic caring,
embodied in nursing practice (Baummann
et al., 1998). Furthermore, despite acquiring
new skills and knowledge through the ac-
credited training nurses have to undertake be-
fore prescribing, there have been concerns
that nurses’ pharmacologic knowledge re-
mains inadequate for prescribing responsibil-
ities (Leathard, 2001; Offredy et al., 2007; So-
dah et al., 2002), a concern not considered
problematic (Fawcett, 2007) for the second
NMP stakeholders to be considered as pre-
scribers: pharmacists.
The pharmacy profession
In contrast to nursing, pharmacist prescrib-
ing in the United Kingdom was a later devel-
opment that arose from the recommendations
of the second Crown report into the prescrib-
ing and supply of medicines (DoH, 1999) al-
though earlier reports (Nuffield Report, 1986)
had highlighted the need for pharmacists to
take on new roles. From a professional per-
spective, there was concern about deskilling
and dissatisfaction with current roles, par-
ticularly in the community or “retail” sector
(Bissell et al., in press). From a policy perspec-
tive, the government recognized that pharma-
cists represented an underutilized healthcare
group in the United Kingdom (DoH, 2005).
Prescribing, it seemed, might address both
these issues. Despite having enjoyed some in-
creased control over medicines because of
deregulation of POMs (Britten, 2001), the
promise of NMP provided a welcome oppor-
tunity for a profession that has been con-
sidered restricted by occupational limitation
(Turner, 1995) and isolation (Cooper, 2007)
to not only to increase their professional au-
tonomy but also to develop, in the commu-
nity setting, closer links with the primary
care team. Like nurses, pharmacists appear
to have welcomed their prescribing role ac-
cording to the published literature (George
et al., 2006; Weiss et al., 2006), and although
this is presently limited mainly to supplemen-
tary prescribing (almost 1300 pharmacists
are now qualified to undertake supplemen-
tary prescribing but only 153 independent
prescribing; Royal Pharmaceutical Society of
Great Britain, oral communication, 2007),
many expect and want to become indepen-
dent prescribers (Lloyd & Hughes, 2007; War-
chal et al., 2006).
Perhaps, a key difference between nurse
and pharmacist prescribing, however, is
that claims about inadequate pharmacologic
knowledge have not been leveled at the phar-
macy profession in contrast to the nursing
profession (Avery & James, 2007; Horton,
2003). NMP has not been without problems
on a practical level, however; both pharma-
cists and nurses have identified problems with
the implementation of their prescribing, and,
as regard to supplementary prescribing, have
criticized the inflexible, time-consuming na-
ture of CMPs, delays in practicing, problems
accessing patients’ records, and a lack of sup-
port at various levels (employers, peers, doc-
tors, financial, and information technology)
(Cooper et al., 2008).
The medical profession
NMP potentially offers doctors a number
of benefits and it has been anticipated that
it will reduce doctors’ workloads and result
in “freeing up their time to concentrate on
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patients with more complicated conditions
and more complex treatments” (DoH, 2005,
¶10). It might also be argued that such ben-
efits would also strengthen doctor’s profes-
sional dominance through increasing the in-
determinacy of their work in such complex
cases in contrast to the increasingly reg-
ulated, technical, and routinized nature of
prescribing (that is informed by evidence-
based medicine and guidelines from bod-
ies such as the National Institute of Health
and Clinical Excellence). This would increase
what has been referred to as the indetermi-
nacy/technicality (I/T) ratio of doctors’ work
and help to further distance doctors from
patients and other healthcare professionals
and enhance their status (Jamous & Peloille,
1970). However, UK doctors have not been
spared significant changes and even threats
to their work and professional autonomy de-
spite traditionally being regarded as the dom-
inant profession in the healthcare division of
labor (Britten, 2001; Friedson, 1970; Turner,
1995; Weiss & Fitzpatrick, 1997). Beside the
threats of proletarianization (due to routiniza-
tion and bureaucratization of medical roles)
and deprofessionalization (due to an increas-
ingly sophisticated lay public; Britten, 2001),
the introduction of NMP might be considered
another challenge and a possible encroach-
ment on doctors’ territory (Eaton & Webb,
1979).
Research also suggests that doctors do
feel threatened by pharmacist prescribing
(Buckley et al., 2006; Child & Cantrill, 1999;
Hughes & McCann, 2003) and that, for nurse
prescribing, there may be a resulting confu-
sion or blurring of professional boundaries
(Hay et al., 2004). Other studies, however,
have indicated generally positive attitudes
toward NMP by some doctors and espe-
cially those involved in mentoring supplemen-
tary prescribing nurses and pharmacists (eg,
Avery et al., 2004; Lloyd & Hughes, 2007). De-
spite this, a number of critical voices within
the medical profession have emerged. Horton
(2002), for example, has argued that nurse
prescribing represents a “dangerous and un-
controlled experiment,” and Keighley (2006)
has questioned the safety and financial secu-
rity of permitting nurses to prescribe from a
full formulary. Independent rather than sup-
plementary prescribing appeared to be par-
ticularly contentious, raising concerns about
the diagnostic competencies of NMP nurses
and also pharmacists. Patient safety and costs
appear to be commonly invoked concerns
among doctors, and Avery and Pringle (2005)
have argued that a lack of research into
safety and costs has fueled the controversy
of too rapid a development of NMP. Percep-
tions of safety and competencies have been
researched, though, revealing conservative,
responsible attitudes among nurses (Bradley
et al., 2007) and prescribing that was gener-
ally informed by accepted standards (Latter
et al., 2007). One paradoxical finding is that
despite the concerns emerging from sec-
tions of the medical profession about NMP,
research suggests that doctors may lack aware-
ness and understanding of NMP and supple-
mentary prescribing in particular (Hughes &
McCann, 2003; Weiss et al., 2006).
Government
NMP represents part of the UK govern-
ments’ plans to modernize the NHS and was
intended to lead to explicit benefits in break-
ing down traditional hierarchies and so “shat-
ter the old demarcations which have held
back staff and slowed down care” (DoH,
2000a, p. 83; 2000b). Five key aims were iden-
tified (Table 2), including changes in the roles
undertaken by healthcare professionals, but
Table 2. Government aims of nonmedical pre-
scribing in the United Kingdom (DoH, 2006)
Improve patient care without
compromising patient safety
Make it easier for patients to get the
medicines they need
Increase patient choice in accessing
medicines
Make better use of the skills of healthcare
professional
Contribute to the introduction of more
flexible team working across the
National Health Service
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patient benefits were always a priority. It has
also been argued that NMP would lead to
several implicit benefits for the government,
primarily in relation to economic cost sav-
ings, and these are apparent in some sections
of the medical professions’ critique of NMP
(Keighley, 2006).
Furthermore, McCartney et al. (1999) argue
that plans for nurse prescribing are wrong to
be viewed in terms of increasing patients’ ac-
cess to medicines and professionalizing nurs-
ing. Instead, they claim NMP for nurses is an
exercise in saving money by using cheaper
staff to prescribe, disguising a shortage of doc-
tors by transferring routine prescribing and,
politically, sending a message to the medi-
cal profession that their power can be dimin-
ished, if necessary, by the government. How-
ever, it may also be argued that the pace of
NMP development in the United Kingdom to-
gether with government funding of NMP train-
ing (at strategic healthcare authority level)
indicates the government’s commitment to
this healthcare initiative. Therefore, the UK
government represents a significant driver in
spite of claims that NMP might have been
introduced hastily in the last decade (Avery
& Pringle, 2005; Horton, 2003; Mazhindu &
Brownsell, 2003).
Patients
As noted in the UK government’s aims for
NMP, patients are described as being central
and the benefits that are claimed for patients
include a reduction in waiting times for treat-
ment, consultations, and obtaining medicines.
NMP may also be congruent with recent gov-
ernment concerns about seeking greater pa-
tient involvement in their care given that sup-
plementary prescribing, for example, requires
the patient to agree to the development of a
CMP, and indeed, the accreditation of NMP
courses is contingent upon prescribers be-
ing able to demonstrate a commitment to pa-
tient involvement in the prescribing consulta-
tion. Unfortunately, little research has directly
involved or engaged patients and the pub-
lic in relation to NMP (Cooper et al., 2008),
but what studies there are reveal that both
nurse and pharmacist prescribing is valued by
patients: in the primary care setting, nurses’
prescribing was viewed positively because of
claims that nurses knew the patient and their
condition well (Luker et al., 1998), while also
providing information, reassurance, and con-
tinuity of care (Brooks et al., 2001). Research
indicates that pharmacist supplementary pre-
scribing was valued by patients (Smalley,
2006) and resulted in more medicines infor-
mation being provided and longer consulta-
tions than with their doctor (Weiss et al.,
2006). Patients also recognized that NMP may
reduce the workload of their doctor (Brooks
et al., 2001; Weiss et al., 2006), and a random
sample of the public was overall confident
about nurse prescribing (Berry et al., 2006).
A point about which patients may be ex-
pected to be concerned is the safety of
NMP. As noted, there is scant research to
underpin doctors’ claims that NMP may be
detrimental to patient safety, but issues such
as nurses’ lack of pharmacologic knowledge
(Offredy et al., 2007) may be significant and
further research is needed to help inform such
concerns.
THE FUTURE OF NMP IN THE
UNITED KINGDOM
NMP in the United Kingdom still repre-
sents a small percentage of the overall pre-
scribing in community and primary care: in
2006 in England, nurses prescribed 6,307,506
items and pharmacists only 31,052 items,
representing 0.8% and 0.004%, respectively,
of the overall volume of some 751,954,100
items prescribed (Guillaume et al., in press;
Horner, 2007). However, the trend overall is
toward significant increases year on year for
nurses and pharmacists, and, for independent
nurse prescribing, this has increasingly in-
cluded medicines, such as antibiotics, previ-
ously prescribed only by doctors (Prescribing
Support Unit, 2007). As regards the future of
NMP, it is anticipated that further increases in
prescribing volume will occur as more phar-
macists qualify independently, and there are
proposals as well for optometrists to become
independent prescribers. This also calls into
question the education and training of those
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hoping to undertake NMP and this may be a
significant factor and require changes in the
future for the success of NMP. As Avery and
James (2007) note, enduring concerns about
nurses’ lack of pharmacologic knowledge and
pharmacists’ lack of diagnostic and exami-
nation skills may require the integration of
NMP training into the undergraduate curric-
ula of these professions instead of what they
consider to be the inadequate present 26-day
course and 12-day learning in practice. This
may also address concerns about the number
of NMP courses nationally that teach nurses,
pharmacists, and allied healthcare profession-
als together despite each professions’ poten-
tially very different educational needs.
CONCLUSIONS
The introduction of NMP in the United
Kingdom has been relatively rapid and also
ambitious in embracing not only nurses and
pharmacists but also, more recently, other
allied healthcare professionals while trying
to balance a number of competing profes-
sional concerns. The question of whose in-
terests NMP serves is not an easy one to
answer because there appear to be conflict-
ing arguments about benefits, even among
individual stakeholder groups: for nurses, in
particular, it would appear that their profes-
sional interests are served by greater clini-
cal autonomy and better working practices
with NMP, but may also be detrimentally af-
fected if they are viewed as being merely ex-
ploited as a “cheaper” source of labor, who
are being asked to move away from the tra-
ditional guiding principles of caring. For the
medical profession, too, there is a tension
between viewing NMP as a mechanism that
will lead to improved working practice or a
threat to professional dominance and power
within the healthcare division of labor. The
conflicting views expressed by doctors pos-
itively involved in NMP mentoring, and those
who hold critical views about the entire
NMP enterprise make it difficult to determine
whether NMP is ultimately in the interests of
the medical profession. It appears likely, how-
ever, that NMP in the United Kingdom will
continue to expand and the issues and in-
terests explored in this article—professional
autonomy, boundary encroachment, patient-
centered policy, and economic costs—will
continue to not only drive these develop-
ments but also cause potential conflict.
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